Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAldoxorubicin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Aldoxorubicin
- Accession Number
- DB06013
- Type
- Small Molecule
- Groups
- Investigational
- Description
Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
- Structure
Structure for DB06013 (Aldoxorubicin)
- Synonyms
- Not Available
- External IDs
- INNO-206
- Product Ingredients
Ingredient UNII CAS InChI Key Aldoxorubicin hydrochloride S098K6HGD9 1361563-03-2 NGKHWQPYPXRQTM-UKFSEGPMSA-N - Categories
- UNII
- C28MV4IM0B
- CAS number
- 1361644-26-9
- Weight
- Average: 750.758
Monoisotopic: 750.274837428 - Chemical Formula
- C37H42N4O13
- InChI Key
- OBMJQRLIQQTJLR-USGQOSEYSA-N
- InChI
- InChI=1S/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+/t17-,20-,22-,27-,32+,37-/m0/s1
- IUPAC Name
- N'-[(1E)-1-[(2S,4S)-4-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide
- SMILES
- COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)C(\CO)=N\NC(=O)CCCCCN4C(=O)C=CC4=O)C(O)=C3C(=O)C2=CC=C1
Pharmacology
- Indication
Investigated for use/treatment in solid tumors.
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
INNO-206 is the (6-Maleimidocaproyl) hydrazone of doxorubicin. INNO-206 is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker. In preclinical models, INNO-206 was superior to doxorubicin with regard to antitumor efficacy and toxicity.
Target Actions Organism ADNA topoisomerase 2-alpha inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Aceclofenac Aceclofenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Acemetacin Acemetacin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Experimental, Investigational Acetyldigitoxin The serum concentration of Acetyldigitoxin can be decreased when it is combined with Aldoxorubicin. Approved Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Aldoxorubicin. Experimental Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Adapalene Adapalene may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Alclofenac Alclofenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Withdrawn Alcuronium Aldoxorubicin may increase the respiratory depressant activities of Alcuronium. Experimental Alendronic acid Aldoxorubicin may increase the hypocalcemic activities of Alendronic acid. Approved Alminoprofen Alminoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Amdinocillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Amdinocillin. Investigational, Withdrawn Amoxicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Amoxicillin. Approved, Vet Approved Amphotericin B Amphotericin B may increase the nephrotoxic activities of Aldoxorubicin. Approved, Investigational Ampicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Ampicillin. Approved, Vet Approved Andrographolide Andrographolide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Anisodamine Anisodamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Antipyrine Antipyrine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Apocynin Apocynin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Apremilast Apremilast may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Aspoxicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Aspoxicillin. Experimental Atracurium Aldoxorubicin may increase the respiratory depressant activities of Atracurium. Approved, Experimental, Investigational Atracurium besylate Aldoxorubicin may increase the respiratory depressant activities of Atracurium besylate. Approved Azapropazone Azapropazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Azelastine Azelastine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Azidocillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Azidocillin. Approved Azlocillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Azlocillin. Approved Azosemide The serum concentration of Aldoxorubicin can be increased when it is combined with Azosemide. Investigational Bacampicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Bacampicillin. Approved, Investigational Balsalazide Balsalazide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Bendazac Bendazac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Benorilate Benorilate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Benoxaprofen Benoxaprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Benzathine benzylpenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Benzathine benzylpenicillin. Approved, Vet Approved Benzydamine Benzydamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Benzylpenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Benzylpenicillin. Approved, Vet Approved Benzylpenicilloyl Polylysine The serum concentration of Aldoxorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine. Approved Bevonium Bevonium may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Botulinum Toxin Type A Aldoxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B Aldoxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B. Approved, Investigational Bromfenac Bromfenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Bucillamine Bucillamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Bufexamac Bufexamac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Experimental Bumadizone Bumadizone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Bumetanide The serum concentration of Aldoxorubicin can be increased when it is combined with Bumetanide. Approved Capreomycin Capreomycin may increase the neuromuscular blocking activities of Aldoxorubicin. Approved Carbaspirin calcium Carbaspirin calcium may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental, Investigational Carbenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Carbenicillin. Approved, Investigational Carbenicillin indanyl The serum concentration of Aldoxorubicin can be decreased when it is combined with Carbenicillin indanyl. Approved, Investigational Carboplatin Aldoxorubicin may increase the ototoxic activities of Carboplatin. Approved Carfecillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Carfecillin. Experimental Carprofen Carprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved, Withdrawn Castanospermine Castanospermine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Celecoxib Celecoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Chloroquine Chloroquine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Vet Approved Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Cisatracurium Aldoxorubicin may increase the respiratory depressant activities of Cisatracurium. Approved Cisplatin Cisplatin may increase the nephrotoxic activities of Aldoxorubicin. Approved Clodronic Acid Aldoxorubicin may increase the hypocalcemic activities of Clodronic Acid. Approved, Investigational, Vet Approved Clonixin Clonixin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Cloxacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Cloxacillin. Approved, Investigational, Vet Approved Colistimethate Aldoxorubicin may increase the nephrotoxic activities of Colistimethate. Approved, Vet Approved Curcumin Curcumin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Cyclacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Cyclacillin. Approved Cyclosporine Aldoxorubicin may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Cymarin The serum concentration of Cymarin can be decreased when it is combined with Aldoxorubicin. Experimental Decamethonium Aldoxorubicin may increase the respiratory depressant activities of Decamethonium. Approved Deslanoside The serum concentration of Deslanoside can be decreased when it is combined with Aldoxorubicin. Approved Diclofenac Diclofenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Dicloxacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Dicloxacillin. Approved, Investigational, Vet Approved Difenpiramide Difenpiramide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Diflunisal Diflunisal may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Aldoxorubicin. Approved, Investigational Digoxin The serum concentration of Digoxin can be decreased when it is combined with Aldoxorubicin. Approved Digoxin Immune Fab (Ovine) The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Aldoxorubicin. Approved Domoic Acid Aldoxorubicin may increase the respiratory depressant activities of Domoic Acid. Experimental Doxacurium chloride Aldoxorubicin may increase the respiratory depressant activities of Doxacurium chloride. Approved Droxicam Droxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Duvelisib Duvelisib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational E-6201 E-6201 may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Epicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Epicillin. Experimental Epirizole Epirizole may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Etacrynic acid The serum concentration of Aldoxorubicin can be increased when it is combined with Etacrynic acid. Approved, Investigational Etanercept Etanercept may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Ethenzamide Ethenzamide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Etidronic acid Aldoxorubicin may increase the hypocalcemic activities of Etidronic acid. Approved Etodolac Etodolac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Vet Approved Etofenamate Etofenamate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Etoricoxib Etoricoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Evening primrose oil Evening primrose oil may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational, Nutraceutical Exisulind Exisulind may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Felbinac Felbinac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Fenbufen Fenbufen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Fenoprofen Fenoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Fentiazac Fentiazac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Feprazone Feprazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Ferulic acid Ferulic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Floctafenine Floctafenine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Withdrawn Flucloxacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Flucloxacillin. Approved, Investigational Flunixin Flunixin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Vet Approved Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Flurbiprofen Flurbiprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Foscarnet Foscarnet may increase the nephrotoxic activities of Aldoxorubicin. Approved Furosemide The serum concentration of Aldoxorubicin can be increased when it is combined with Furosemide. Approved, Vet Approved Gallamine Aldoxorubicin may increase the respiratory depressant activities of Gallamine. Experimental Gallamine Triethiodide Aldoxorubicin may increase the respiratory depressant activities of Gallamine Triethiodide. Approved Gitoformate The serum concentration of Gitoformate can be decreased when it is combined with Aldoxorubicin. Experimental Guacetisal Guacetisal may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Higenamine Higenamine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Ibandronate Aldoxorubicin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Ibuprofen Ibuprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Ibuproxam Ibuproxam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Icatibant Icatibant may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Indobufen Indobufen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Indomethacin Indomethacin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Indoprofen Indoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Isoxicam Isoxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn Kebuzone Kebuzone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Ketoprofen Ketoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Ketorolac Ketorolac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Lanatoside C The serum concentration of Lanatoside C can be decreased when it is combined with Aldoxorubicin. Experimental Leflunomide Leflunomide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Lisofylline Lisofylline may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Lonazolac Lonazolac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Lornoxicam Lornoxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Loxoprofen Loxoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Lumiracoxib Lumiracoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Mannitol Mannitol may increase the nephrotoxic activities of Aldoxorubicin. Approved, Investigational Masoprocol Masoprocol may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Mecamylamine Aldoxorubicin may increase the neuromuscular blocking activities of Mecamylamine. Approved, Investigational Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Mefenamic acid Mefenamic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Meloxicam Meloxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Mesalazine Mesalazine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Metamizole Metamizole may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Metampicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Metampicillin. Experimental Meticillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Meticillin. Approved, Investigational Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Aldoxorubicin. Experimental Metocurine Aldoxorubicin may increase the respiratory depressant activities of Metocurine. Approved Metocurine Iodide Aldoxorubicin may increase the respiratory depressant activities of Metocurine Iodide. Approved, Withdrawn Mezlocillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Mezlocillin. Approved, Investigational Mivacurium Aldoxorubicin may increase the respiratory depressant activities of Mivacurium. Approved Mizoribine Mizoribine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Mofebutazone Mofebutazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Mycophenolate mofetil Mycophenolate mofetil may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Mycophenolic acid Mycophenolic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Nabumetone Nabumetone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Nafamostat Nafamostat may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Nafcillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Nafcillin. Approved, Investigational Naftifine Naftifine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Naproxen Naproxen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Neosaxitoxin Aldoxorubicin may increase the respiratory depressant activities of Neosaxitoxin. Investigational Nepafenac Nepafenac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Nifenazone Nifenazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Niflumic Acid Niflumic Acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Nimesulide Nimesulide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Nitroaspirin Nitroaspirin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Oleandrin The serum concentration of Oleandrin can be decreased when it is combined with Aldoxorubicin. Experimental, Investigational Olopatadine Olopatadine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Olsalazine Olsalazine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Orgotein Orgotein may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Vet Approved Ouabain The serum concentration of Ouabain can be decreased when it is combined with Aldoxorubicin. Approved Oxacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Oxacillin. Approved, Investigational Oxaprozin Oxaprozin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Withdrawn Pamidronate Aldoxorubicin may increase the hypocalcemic activities of Pamidronate. Approved Pancuronium Aldoxorubicin may increase the respiratory depressant activities of Pancuronium. Approved Parecoxib Parecoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Parthenolide Parthenolide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Penamecillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Penamecillin. Experimental Penimepicycline The serum concentration of Aldoxorubicin can be decreased when it is combined with Penimepicycline. Experimental Peruvoside The serum concentration of Peruvoside can be decreased when it is combined with Aldoxorubicin. Experimental Phenoxymethylpenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Phenoxymethylpenicillin. Approved, Vet Approved Phenylbutazone Phenylbutazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Vet Approved Pimecrolimus Pimecrolimus may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Pipecuronium Aldoxorubicin may increase the respiratory depressant activities of Pipecuronium. Approved Piperacillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Piperacillin. Approved Piretanide The serum concentration of Aldoxorubicin can be increased when it is combined with Piretanide. Approved Pirfenidone Pirfenidone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Piroxicam Piroxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Pirprofen Pirprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Pivampicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Pivampicillin. Approved Pivmecillinam The serum concentration of Aldoxorubicin can be decreased when it is combined with Pivmecillinam. Approved Pranoprofen Pranoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental, Investigational Procaine benzylpenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Procaine benzylpenicillin. Approved, Vet Approved Proglumetacin Proglumetacin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Propacetamol Propacetamol may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Propicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Propicillin. Experimental Propyphenazone Propyphenazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Proquazone Proquazone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Proscillaridin The serum concentration of Proscillaridin can be decreased when it is combined with Aldoxorubicin. Experimental PTC299 PTC299 may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Pyrantel Aldoxorubicin may increase the respiratory depressant activities of Pyrantel. Approved, Vet Approved Rapacuronium Aldoxorubicin may increase the respiratory depressant activities of Rapacuronium. Withdrawn Resveratrol Resveratrol may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Experimental, Investigational Risedronate Aldoxorubicin may increase the hypocalcemic activities of Risedronate. Approved, Investigational Rocuronium Aldoxorubicin may increase the respiratory depressant activities of Rocuronium. Approved Rofecoxib Rofecoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Salicylamide Salicylamide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Salicylic acid Salicylic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Vet Approved Salsalate Salsalate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Semapimod Semapimod may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Seratrodast Seratrodast may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Serrapeptase Serrapeptase may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational SRT501 SRT501 may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Succinylcholine Aldoxorubicin may increase the respiratory depressant activities of Succinylcholine. Approved Sulbactam The serum concentration of Aldoxorubicin can be decreased when it is combined with Sulbactam. Approved Sulbenicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Sulbenicillin. Experimental Sulfasalazine Sulfasalazine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Sulindac Sulindac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Sultamicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Sultamicillin. Approved, Investigational Suprofen Suprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Withdrawn Suxibuzone Suxibuzone may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Talampicillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Talampicillin. Experimental Tarenflurbil Tarenflurbil may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Tazobactam The serum concentration of Aldoxorubicin can be decreased when it is combined with Tazobactam. Approved Technetium Tc-99m etidronate Aldoxorubicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate Aldoxorubicin may increase the hypocalcemic activities of Technetium Tc-99m medronate. Approved Tenidap Tenidap may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Tenofovir disoproxil The serum concentration of Aldoxorubicin can be increased when it is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam Tenoxicam may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Tepoxalin Tepoxalin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Vet Approved Teriflunomide Teriflunomide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Ticarcillin The serum concentration of Aldoxorubicin can be decreased when it is combined with Ticarcillin. Approved, Investigational, Vet Approved Tiludronic acid Aldoxorubicin may increase the hypocalcemic activities of Tiludronic acid. Approved, Investigational, Vet Approved Tinoridine Tinoridine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Tolfenamic Acid Tolfenamic Acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Tolmetin Tolmetin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved Torasemide The serum concentration of Aldoxorubicin can be increased when it is combined with Torasemide. Approved Tranilast Tranilast may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Tribenoside Tribenoside may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Experimental Triptolide Triptolide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Investigational Tubocurarine Aldoxorubicin may increase the respiratory depressant activities of Tubocurarine. Approved Valdecoxib Valdecoxib may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Vancomycin Vancomycin may increase the nephrotoxic activities of Aldoxorubicin. Approved Vecuronium Aldoxorubicin may increase the respiratory depressant activities of Vecuronium. Approved Zaltoprofen Zaltoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational Zileuton Zileuton may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Zoledronic acid Aldoxorubicin may increase the hypocalcemic activities of Zoledronic acid. Approved Zomepirac Zomepirac may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- KEGG Drug
- D10383
- ChemSpider
- 7986464
- ChEMBL
- CHEMBL2107818
- Wikipedia
- Aldoxorubicin
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.151 mg/mL ALOGPS logP 1.26 ALOGPS logP 0.71 ChemAxon logS -3.7 ALOGPS pKa (Strongest Acidic) 8.2 ChemAxon pKa (Strongest Basic) 9.39 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 15 ChemAxon Hydrogen Donor Count 7 ChemAxon Polar Surface Area 267.84 Å2 ChemAxon Rotatable Bond Count 12 ChemAxon Refractivity 189.86 m3·mol-1 ChemAxon Polarizability 75.89 Å3 ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Ubiquitin binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
- Gene Name
- TOP2A
- Uniprot ID
- P11388
- Uniprot Name
- DNA topoisomerase 2-alpha
- Molecular Weight
- 174383.88 Da
References
- Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt DJ: A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb 15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. [PubMed:25312684]
Drug created on November 18, 2007 11:29 / Updated on May 02, 2018 01:45